Hemiplegia

Summary

Hemiplegia (MONDO:0001170) is a disease with 5 cohort genes (2 GWAS associations across 13 studies) and 222 clinical trials. The dominant Reactome pathway is Muscle contraction (4 cohort genes).

At a glance

• Cohort genes: 5
• GWAS associations: 2
• ClinVar variants: 8
• Clinical trials: 222

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	hemiplegia
Mondo ID	MONDO:0001170
EFO	EFO:0009453
MeSH	D006429
DOID	DOID:10969
ICD-11	1641958762
SNOMED CT	1593000
UMLS	C0018991
MedGen	9196
Is cancer (heuristic)	no

Data availability: 8 ClinVar variants · 2 GWAS associations (13 studies).

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › palsy › hemiplegia

Related subtypes (9): quadriplegia, facial paralysis, ophthalmoplegia, paraplegia, cerebral palsy, progressive bulbar palsy, klumpke’s paralysis, respiratory paralysis, Erb palsy

Subtypes (1): alternating hemiplegia of childhood

Genetics & variants

GWAS landscape

2 GWAS associations across 13 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs186664432	4e-12	TLK1 - METTL8	G	2.34
rs137951129	5e-09	DPP6	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90473361	UK Biobank Whole-Genome Sequencing Consortium	2025	4,617	453,823	Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90477545	Verma A	2024	2,372	445,320	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90079854	Backman JD	2021	2,070	385,551	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083840	Backman JD	2021	2,070	385,551	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90079853	Backman JD	2021	2,024	385,757	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90083839	Backman JD	2021	2,024	385,757	Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90435923	Zhou W	2018	1,500	395,209	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90477544	Verma A	2024	1,135	119,261	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480018	Verma A	2024	1,135	119,261	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651396	Liu TY	2025	550	218,635	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	2

MAF distribution

Bucket	Variants
common (>=0.05)	0
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	1

Functional consequences

Consequence	Count
intergenic_variant	1
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs186664432	2	171303214	G>A	0	intergenic_variant	TLK1 - METTL8	4e-12	Tier 4: intronic/intergenic
rs137951129	7	154373184	T>C		intron_variant	DPP6	5e-09	Tier 4: intronic/intergenic

ClinVar germline variants

8 retrieved; paginated sample, class counts are floors:

3 conflicting classifications of pathogenicity, 2 pathogenic, 1 likely pathogenic, 1 pathogenic/likely pathogenic, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
37108	NM_152296.5(ATP1A3):c.2443G>A (p.Glu815Lys)	ATP1A3	Pathogenic	criteria provided, multiple submitters, no conflicts
37110	NM_152296.5(ATP1A3):c.2839G>A (p.Gly947Arg)	ATP1A3	Pathogenic	criteria provided, multiple submitters, no conflicts
523558	NM_152296.5(ATP1A3):c.958G>C (p.Ala320Pro)	ATP1A3	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
4813501	NM_000702.4(ATP1A2):c.3022del (p.Arg1008fs)	ATP1A2	Likely pathogenic	no assertion criteria provided
44926	NM_004415.4(DSP):c.5218G>A (p.Glu1740Lys)	DSP	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
14149	NM_002471.4(MYH6):c.3195G>C (p.Gln1065His)	MYH6	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
239175	NM_002471.4(MYH6):c.4594C>T (p.Arg1532Cys)	MYH6	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
9387	NM_000335.5(SCN5A):c.892G>A (p.Gly298Ser)	SCN5A	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 29 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
SCN5A	Orphanet:101016	Romano-Ward syndrome
SCN5A	Orphanet:130	Brugada syndrome
SCN5A	Orphanet:1344	Isolated atrial standstill
SCN5A	Orphanet:154	Familial isolated dilated cardiomyopathy
SCN5A	Orphanet:166282	Hereditary sick sinus syndrome
SCN5A	Orphanet:228140	Idiopathic ventricular fibrillation
SCN5A	Orphanet:334	Hereditary atrial fibrillation
SCN5A	Orphanet:871	Hereditary progressive cardiac conduction defect
DSP	Orphanet:154	Familial isolated dilated cardiomyopathy
DSP	Orphanet:158687	Lethal acantholytic erosive disorder
DSP	Orphanet:2032	Idiopathic pulmonary fibrosis
DSP	Orphanet:293165	Skin fragility-woolly hair-palmoplantar keratoderma syndrome
DSP	Orphanet:293888	Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant
DSP	Orphanet:293899	Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant
DSP	Orphanet:293910	Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant
DSP	Orphanet:369992	Severe dermatitis-multiple allergies-metabolic wasting syndrome
DSP	Orphanet:476096	Erythrokeratodermia-cardiomyopathy syndrome
DSP	Orphanet:50942	Striate palmoplantar keratoderma
DSP	Orphanet:65282	Carvajal syndrome
MYH6	Orphanet:154	Familial isolated dilated cardiomyopathy
MYH6	Orphanet:166282	Hereditary sick sinus syndrome
MYH6	Orphanet:99103	Atrial septal defect, ostium secundum type
ATP1A2	Orphanet:2131	Alternating hemiplegia of childhood
ATP1A2	Orphanet:442835	Non-specific early-onset epileptic encephalopathy
ATP1A2	Orphanet:569	Familial or sporadic hemiplegic migraine
ATP1A3	Orphanet:1171	Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome
ATP1A3	Orphanet:2131	Alternating hemiplegia of childhood
ATP1A3	Orphanet:442835	Non-specific early-onset epileptic encephalopathy
ATP1A3	Orphanet:71517	Rapid-onset dystonia-parkinsonism

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
SCN5A	HGNC:10593	ENSG00000183873	Q14524	Sodium channel protein type 5 subunit alpha	clinvar
DSP	HGNC:3052	ENSG00000096696	P15924	Desmoplakin	clinvar
MYH6	HGNC:7576	ENSG00000197616	P13533	Myosin-6	clinvar
ATP1A2	HGNC:800	ENSG00000018625	P50993	Sodium/potassium-transporting ATPase subunit alpha-2	clinvar
ATP1A3	HGNC:801	ENSG00000105409	P13637	Sodium/potassium-transporting ATPase subunit alpha-3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
SCN5A	Sodium channel protein type 5 subunit alpha	Pore-forming subunit of Nav1.5, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.
DSP	Desmoplakin	A component of desmosome cell-cell junctions which are required for positive regulation of cellular adhesion.
MYH6	Myosin-6	Muscle contraction.
ATP1A2	Sodium/potassium-transporting ATPase subunit alpha-2	This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane.
ATP1A3	Sodium/potassium-transporting ATPase subunit alpha-3	This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane.

Protein-family classification

Druggable: 1 · Difficult: 4 · Unknown: 0 · Druggable fraction: 0.2

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Ion channel	1	22.3×	0.066
Scaffold/PPI	2	6.9×	0.066
Transcription factor	2	3.3×	0.114

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
SCN5A	Ion channel	yes		Na_channel_asu, Ion_trans_dom, Na_channel_a5su
DSP	Scaffold/PPI	no		Plectin_repeat, SH3_domain, Spectrin/alpha-actinin
MYH6	Scaffold/PPI	no		Myosin_head_motor_dom-like, Myosin_tail, SH3_Myosin
ATP1A2	Transcription factor	no		P_typ_ATPase, ATPase_P-typ_cation-transptr_N, P-type_ATPase_IIC
ATP1A3	Transcription factor	no		P_typ_ATPase, ATPase_P-typ_cation-transptr_N, P-type_ATPase_IIC

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
apex of heart	1
cardiac ventricle	1
heart left ventricle	1
hair follicle	1
skin of hip	1
upper leg skin	1
cardiac atrium	1
cardiac muscle of right atrium	1
vena cava	1
lateral globus pallidus	1
superior vestibular nucleus	1
trigeminal ganglion	1
cortical plate	1
primary visual cortex	1
superior frontal gyrus	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
SCN5A	161	broad	yes	apex of heart, heart left ventricle, cardiac ventricle
DSP	253	ubiquitous	marker	skin of hip, upper leg skin, hair follicle
MYH6	154	tissue_specific	yes	cardiac muscle of right atrium, cardiac atrium, vena cava
ATP1A2	262	broad	marker	lateral globus pallidus, trigeminal ganglion, superior vestibular nucleus
ATP1A3	129	broad	marker	superior frontal gyrus, primary visual cortex, cortical plate

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ATP1A3	3,876
MYH6	3,119
DSP	2,897
ATP1A2	2,679
SCN5A	2,090

Intra-cohort edges

A	B	Sources
ATP1A2	ATP1A3	intact, string_interaction

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
SCN5A	Q14524	16
ATP1A3	P13637	5
DSP	P15924	4

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
ATP1A2	P50993	88.25
MYH6	P13533	74.91

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 24. Enrichment computed across 5 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Muscle contraction	4	61.7×	3e-06	SCN5A, MYH6, ATP1A2, ATP1A3
Cardiac conduction	3	65.3×	9e-05	SCN5A, ATP1A2, ATP1A3
Ion transport by P-type ATPases	2	83.0×	0.001	ATP1A2, ATP1A3
Ion homeostasis	2	81.6×	0.001	ATP1A2, ATP1A3
Potential therapeutics for SARS	2	45.7×	0.004	ATP1A2, ATP1A3
Ion channel transport	2	38.4×	0.004	ATP1A2, ATP1A3
SARS-CoV Infections	2	22.2×	0.011	ATP1A2, ATP1A3
Apoptotic cleavage of cell adhesion proteins	1	207.6×	0.014	DSP
Viral Infection Pathways	2	12.3×	0.026	ATP1A2, ATP1A3
Interaction between L1 and Ankyrins	1	73.7×	0.028	SCN5A
Phase 0 - rapid depolarisation	1	69.2×	0.028	SCN5A
Transport of small molecules	2	10.1×	0.028	ATP1A2, ATP1A3
Infectious disease	2	9.9×	0.028	ATP1A2, ATP1A3
Striated Muscle Contraction	1	61.7×	0.028	MYH6
RND1 GTPase cycle	1	53.1×	0.029	DSP
RND3 GTPase cycle	1	51.9×	0.029	DSP
L1CAM interactions	1	24.0×	0.058	SCN5A
Disease	2	5.2×	0.067	ATP1A2, ATP1A3
Formation of the cornified envelope	1	17.6×	0.070	DSP
Keratinization	1	11.1×	0.104	DSP
Axon guidance	1	9.0×	0.121	SCN5A
Nervous system development	1	8.6×	0.121	SCN5A
Neutrophil degranulation	1	4.6×	0.207	DSP
Developmental Biology	1	2.9×	0.301	SCN5A

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
cardiac muscle contraction	3	240.7×	2e-05	SCN5A, MYH6, ATP1A2
response to glycoside	2	963.0×	8e-05	ATP1A2, ATP1A3
membrane depolarization during cardiac muscle cell action potential	2	561.7×	1e-04	SCN5A, ATP1A2
cell communication by electrical coupling involved in cardiac conduction	2	561.7×	1e-04	ATP1A2, ATP1A3
regulation of cardiac muscle cell contraction	2	449.4×	1e-04	SCN5A, ATP1A2
sodium ion export across plasma membrane	2	421.3×	1e-04	ATP1A2, ATP1A3
cellular response to steroid hormone stimulus	2	421.3×	1e-04	ATP1A2, ATP1A3
regulation of the force of heart contraction	2	396.5×	1e-04	MYH6, ATP1A2
intracellular potassium ion homeostasis	2	396.5×	1e-04	ATP1A2, ATP1A3
intracellular sodium ion homeostasis	2	306.4×	2e-04	ATP1A2, ATP1A3
regulation of heart rate	2	187.2×	4e-04	SCN5A, MYH6
ATP metabolic process	2	187.2×	4e-04	MYH6, ATP1A2
regulation of heart rate by cardiac conduction	2	149.8×	6e-04	SCN5A, DSP
potassium ion import across plasma membrane	2	146.5×	6e-04	ATP1A2, ATP1A3
proton transmembrane transport	2	124.8×	8e-04	ATP1A2, ATP1A3
sodium ion transport	2	108.7×	9e-04	SCN5A, ATP1A2
regulation of blood pressure	2	88.7×	0.001	MYH6, ATP1A2
sodium ion transmembrane transport	2	81.2×	0.001	SCN5A, ATP1A2
visceral muscle development	1	3370.4×	0.002	MYH6
olfactory cortex development	1	3370.4×	0.002	ATP1A2
regulation of glutamate uptake involved in transmission of nerve impulse	1	1685.2×	0.003	ATP1A2
regulation of heart growth	1	1685.2×	0.003	MYH6
bundle of His cell action potential	1	1685.2×	0.003	SCN5A
AV node cell to bundle of His cell communication	1	1685.2×	0.003	SCN5A
negative regulation of calcium ion transmembrane transport	1	1685.2×	0.003	ATP1A2
negative regulation of striated muscle contraction	1	1123.5×	0.003	ATP1A2
membrane depolarization during Purkinje myocyte cell action potential	1	1123.5×	0.003	SCN5A
membrane depolarization during bundle of His cell action potential	1	1123.5×	0.003	SCN5A
membrane depolarization during atrial cardiac muscle cell action potential	1	1123.5×	0.003	SCN5A
negative regulation of heart contraction	1	842.6×	0.004	ATP1A2

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Onabotulinumtoxina	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Triheptanoin.

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 2

Druggability breadth: 5 of 5 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
SCN5A	BEPRIDIL
ATP1A2	OMEPRAZOLE
ATP1A3	OMEPRAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
SCN5A	108	4
ATP1A2	5	4
ATP1A3	5	4
DSP	0	0
MYH6	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BEPRIDIL	4	SCN5A
CANDESARTAN CILEXETIL	4	SCN5A
TELMISARTAN	4	SCN5A
CARBAMAZEPINE	4	SCN5A
DIBUCAINE	4	SCN5A
IMIPRAMINE	4	SCN5A
DROPERIDOL	4	SCN5A
PONATINIB	4	SCN5A
DULOXETINE	4	SCN5A
PALONOSETRON	4	SCN5A
VILANTEROL	4	SCN5A
MEXILETINE HYDROCHLORIDE	4	SCN5A
UNOPROSTONE ISOPROPYL	4	SCN5A
LURASIDONE	4	SCN5A
LETERMOVIR	4	SCN5A
SERTINDOLE	4	SCN5A
FEDRATINIB	4	SCN5A
QUINIDINE	4	SCN5A
DARUNAVIR	4	SCN5A
DARIFENACIN	4	SCN5A
BENZONATATE	4	SCN5A
TOLTERODINE	4	SCN5A
RANOLAZINE	4	SCN5A
PIMOZIDE	4	SCN5A
NIMODIPINE	4	SCN5A
FELODIPINE	4	SCN5A
NICARDIPINE	4	SCN5A
AMLODIPINE	4	SCN5A
PHENYTOIN	4	SCN5A
PALIPERIDONE	4	SCN5A

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
SCN5A	594	Binding:380, Functional:98, ADMET:72, Toxicity:43, Unclassified:1
ATP1A2	49	Binding:49
ATP1A3	45	Binding:45
DSP	2	Binding:2

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
SCN5A	594

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BEPRIDIL	4	SCN5A
CANDESARTAN CILEXETIL	4	SCN5A
TELMISARTAN	4	SCN5A
CARBAMAZEPINE	4	SCN5A
DIBUCAINE	4	SCN5A
IMIPRAMINE	4	SCN5A
DROPERIDOL	4	SCN5A
PONATINIB	4	SCN5A
DULOXETINE	4	SCN5A
PALONOSETRON	4	SCN5A
VILANTEROL	4	SCN5A
MEXILETINE HYDROCHLORIDE	4	SCN5A
UNOPROSTONE ISOPROPYL	4	SCN5A
LURASIDONE	4	SCN5A
LETERMOVIR	4	SCN5A
SERTINDOLE	4	SCN5A
FEDRATINIB	4	SCN5A
QUINIDINE	4	SCN5A
DARUNAVIR	4	SCN5A
DARIFENACIN	4	SCN5A
BENZONATATE	4	SCN5A
TOLTERODINE	4	SCN5A
RANOLAZINE	4	SCN5A
PIMOZIDE	4	SCN5A
NIMODIPINE	4	SCN5A
FELODIPINE	4	SCN5A
NICARDIPINE	4	SCN5A
AMLODIPINE	4	SCN5A
PHENYTOIN	4	SCN5A
PALIPERIDONE	4	SCN5A

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	SCN5A, ATP1A2, ATP1A3
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	2	DSP, MYH6

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
DSP	2	—
MYH6	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 222.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	204
PHASE3	5
PHASE1/PHASE2	5
PHASE2	2
PHASE1	2
EARLY_PHASE1	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05260125	PHASE4	RECRUITING	Comparison of the Efficacy of Ultrasound Guided vs Non-guided Suprascapular Nerve Block Treatment in Stroke Patients
NCT00223808	PHASE3	COMPLETED	Assisted Movement Neuro-rehabilitation: VA Multi-site Clinical Trial
NCT00276185	PHASE3	UNKNOWN	HEMITOX : Effect of Botulinum Toxin Injections on Motor and Functional Ability of Upper Limb in Adults at Earlier Phases of Spastic Hemiplegia After Stroke
NCT00632528	PHASE3	COMPLETED	MEOPA to Improve Physical Therapy Results After Multilevel Surgery
NCT01311271	PHASE2/PHASE3	TERMINATED	Effects of the Quantity of Repetitive Transcranial Magnetic Stimulation(rTMS) on the Recovery After Stroke
NCT01799304	PHASE3	COMPLETED	Static and Dynamic Postural Stability in Cerebral Palsy Children
NCT03555825	PHASE3	COMPLETED	Burke-Hocoma Efficiency Study
NCT00369668	PHASE2	COMPLETED	Post Stroke Hand Functions: Bilateral Movements and Electrical Stimulation Treatments
NCT00523523	PHASE1/PHASE2	COMPLETED	Training the Arm and Hand After Stroke Using Auditory Rhythm Cues
NCT00565045	PHASE1/PHASE2	COMPLETED	Treatments for Recovery of Hand Function in Acute Stroke Survivors
NCT01006772	PHASE1/PHASE2	UNKNOWN	Rehabilitation of Early Stroke Patients Using an AFO: an RCT
NCT01010607	PHASE1/PHASE2	UNKNOWN	Use of Tendon Vibration and Mirror for the Improvement of Upper Limb Function and Pain Reduction
NCT01569386	PHASE2	COMPLETED	Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity of Hemiplegics
NCT01700777	PHASE1/PHASE2	UNKNOWN	Bimanual Training in Children With Hemiplegia With Lower Limb and Postural Stimulation (HABIT & Leg)
NCT01072461	PHASE1	COMPLETED	Optimizing Hand Rehabilitation Post-Stroke Using Interactive Virtual Environments
NCT01308216	PHASE1	TERMINATED	Transcranial Laser Therapy in the Rehabilitation of Hemiplegic Patients From Ischemic Stroke
NCT01827436	EARLY_PHASE1	COMPLETED	Asymmetrical Gait Training After Pediatric Stroke
NCT05101707	EARLY_PHASE1	COMPLETED	CIMT and taVNS for Hemiplegia in Infants
NCT03870672	Not specified	RECRUITING	rTMS Plus CCFES-mediated Functional Task Practice for Severe Stroke
NCT04564495	Not specified	ACTIVE_NOT_RECRUITING	Home Based Tele-exercise for People With Chronic Neurological Impairments
NCT04625127	Not specified	ACTIVE_NOT_RECRUITING	GaitBetter: Motor and Cognitive Training for Gait Rehabilitation and Falls Prevention in Stroke Survivors.
NCT04888416	Not specified	ACTIVE_NOT_RECRUITING	Implementing Outcome Measures in Stroke Rehabilitation
NCT05740540	Not specified	RECRUITING	Implant for Walking After Stroke
NCT05828797	Not specified	RECRUITING	Elastography in Patients With Hemiplegia
NCT05866003	Not specified	RECRUITING	tDCS + CCFES-mediated Functional Task Practice for Post-stroke Upper Extremity Hemiplegia
NCT06121947	Not specified	NOT_YET_RECRUITING	Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
NCT06242366	Not specified	RECRUITING	Transitional Care Program in Stroke Patients With Hemiplegia.
NCT06314776	Not specified	RECRUITING	Whole-Body Vibration Therapy in the Gait of Children With Cerebral Palsy
NCT06329765	Not specified	RECRUITING	CUped: An Approach to Motor Recovery Post-Stroke, Not Compensation
NCT06557681	Not specified	ACTIVE_NOT_RECRUITING	The Effect of Virtual Reality Treadmill-Based Gait Training on Gait and Balance Ability in Chronic Stroke Patients
NCT06579027	Not specified	RECRUITING	A Novel Program Using Ride-on Toys to Improve Upper Extremity Function in Children With Hemiplegia
NCT06690073	Not specified	RECRUITING	The Effect of Motor Relearning Program on Functional Mobility in Stroke Rehabilitation.
NCT06692569	Not specified	RECRUITING	The Effect of Modified Constraint Induced Movement Therapy on Upper Extremity Function in Stroke Rehabilitation
NCT06692829	Not specified	NOT_YET_RECRUITING	Robot-Assisted Therapy in Chronic Stroke Patients
NCT06698380	Not specified	RECRUITING	The Effect of Mirror Therapy on Upper Extremity Motor Function in Stroke Rehabilitation
NCT06706063	Not specified	ACTIVE_NOT_RECRUITING	Ultrasonograpy in Hemiplegic Patients
NCT06709222	Not specified	NOT_YET_RECRUITING	Robotic Rehabilitation and Dual-Task Exercises in Hemiplegic Patients
NCT06729190	Not specified	RECRUITING	Effect of Biofeedback and Functional Electrical Stimulation in Children
NCT06782464	Not specified	RECRUITING	Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT06793800	Not specified	RECRUITING	Effect of Transcutaneous Auricular Vagus Nerve Stimulation Application on Respiratory Functions in Stroke Patients

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CHEMBL443232	0	1